Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jennifer Peterson

Dermatology Houston, TX Medical Doctor

NPI 1164614913 CMS profile 7225

550 Post Oak Blvd Ste 550, Houston, TX 77027

Open in the dashboard

General payments

$66,287

363 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$84,007 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Jennifer Peterson of Houston, TX is reported in the CMS Open Payments database as having received $66,287 across 363 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $84,007 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,253 51
2024 General $1,276 46
2023 General $32,708 75
2022 General $3,141 35
2021 General $6,919 29
2020 General $10,106 33
2019 General $9,884 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Peterson
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Jennifer Peterson were reported at $2,253. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Jennifer Peterson Dermatology median Middle half National median
2019 $9,884 $454 $129–$1,240 $163
2020 $10,106 $235 $81–$756 $114
2021 $6,919 $377 $108–$1,108 $132
2022 $3,141 $514 $143–$1,391 $149
2023 $32,708 $607 $159–$1,674 $160
2024 $1,276 $751 $204–$1,903 $164
2025 $2,253 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Galderma Laboratories, L.P. $44,383 93 payments
  2. Merz North America, Inc. $8,678 23 payments
  3. Lumenis, Inc $7,000 2 payments
  4. AbbVie, Inc. $2,540 60 payments
  5. Janssen Biotech, Inc. $442 21 payments
  6. Almirall LLC $402 19 payments
  7. Allergan Inc. $380 25 payments
  8. Incyte Corporation $325 11 payments
  9. Arcutis Biotherapeutics, Inc. $302 13 payments
  10. Mayne Pharma Inc. $226 11 payments
  11. Other $1,611 85 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $46,540 18 payments
  2. Food and Beverage $9,069 328 payments
  3. Consulting Fee $7,441 3 payments
  4. Travel and Lodging $3,121 11 payments
  5. Education $116 3 payments
Products named General payments · program years 2019–2025
  1. AKLIEF $31,709 30 payments
  2. EPSOLAY $26,436 28 payments
  3. ORACEA $25,541 27 payments
  4. TWYNEO $24,033 24 payments
  5. SOOLANTRA $6,238 10 payments
  6. BOTOX $412 17 payments
  7. SKYRIZI $386 24 payments
  8. OPZELURA $325 11 payments
  9. Zoryve $277 12 payments
  10. SIMPONI ARIA $225 9 payments
  11. Other $4,236 220 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

17

Median for Dermatology: 534

Drug cost

$959

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxycycline Hyclate Generic 17 $959

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zoryve
  • Arcutis Biotherapeutics, Inc. $248
$248 — —
BOTOX
  • AbbVie, Inc. $247
$247 — —
OPZELURA
  • Incyte Corporation $148
$148 — —
SKYRIZI
  • AbbVie, Inc. $98
$98 — —
Otezla
  • Amgen Inc. $86
$86 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

363 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record